GSK slims portfolio with sale of rare disease gene therapy drugs

LONDON (Reuters) – GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker’s pharmaceuticals portfolio.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *